Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	653.87M +3.8%
Revenue (ttm)	132.42M -37.0%
Net Income	-290.80M
EPS	-4.96
Shares Out	67.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,280,822
Open	8.50
Previous Close	8.58
Day's Range	8.44 - 9.78
52-Week Range	5.37 - 17.58
Beta	1.77
Analysts	Sell
Price Target	7.00 (-27.91%)
Est. Earnings	Nov 5, 2026

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 485
• Stock Exchange: NYSE
• Ticker Symbol: DNA
• Website: https://www.ginkgo.bio

Financial Performance

In 2025, Ginkgo Bioworks Holdings's revenue was $170.16 million, a decrease of -25.06% compared to the previous year's $227.04 million. Losses were -$312.76 million, -42.83% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for DNA stock is "Sell." The 12-month stock price target is $7.0, which is a decrease of -27.91% from the latest price.

Price Target

$7.0

(-27.91% downside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 24, 2026

Data Sources Report a data error